This HTML5 document contains 61 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00209805%3A_____%2F11%3A%230000184%21RIV12-MZ0-00209805/
n18http://linked.opendata.cz/resource/domain/vavai/projekt/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/resource/domain/vavai/subjekt/
n11http://linked.opendata.cz/ontology/domain/vavai/
n14http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n10http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00209805%3A_____%2F11%3A%230000184%21RIV12-MZ0-00209805
rdf:type
skos:Concept n11:Vysledek
rdfs:seeAlso
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2011.02092.x/pdf
dcterms:description
Glioblastoma multiforme (GBM) is the most frequently occurring primary malignant brain tumor; patients with GBM often have a very poor prognosis and differing responses to treatment. Therefore, it is very important to find new biomarkers that can predict clinical outcomes and help in treatment decisions. MicroRNAs are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and play a key role in the pathogenesis of GBM. In a group of 38 patients with primary GBM, we analyzed the expression of eight microRNAs (miR-21, miR-128a, miR-181c, miR-195, miR-196a, miR-196b, miR-221, and miR-222). In addition, we examined the methylation status of O-6-methylguanine-DNA methyltransferase (MGMT) promoter by high-resolution melting analysis, as this has been shown to be a predictive marker in GBM. MGMT methylation status correlated with progression-free survival (P = 0.0201; logrank test) as well as with overall survival (P = 0.0054; logrank test). MiR-195 (P = 0.0124; logrank test) and miR-196b (P = 0.0492; logrank test) positively correlated with overall survival. Evaluation of miR-181c in combination with miR-21 predicted time to progression within 6 months of diagnosis with 92% sensitivity and 81% specificity (P < 0.0001). Our data confirmed that the methylation status of MGMT but also miR-21, miR-181c, miR-195, and miR-196b to be associated with survival of GBM patients. Above all, we suggest that the combination of miR-181c and miR-21 could be a very sensitive and specific test to identify patients at high risk of early progression after surgery. Glioblastoma multiforme (GBM) is the most frequently occurring primary malignant brain tumor; patients with GBM often have a very poor prognosis and differing responses to treatment. Therefore, it is very important to find new biomarkers that can predict clinical outcomes and help in treatment decisions. MicroRNAs are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and play a key role in the pathogenesis of GBM. In a group of 38 patients with primary GBM, we analyzed the expression of eight microRNAs (miR-21, miR-128a, miR-181c, miR-195, miR-196a, miR-196b, miR-221, and miR-222). In addition, we examined the methylation status of O-6-methylguanine-DNA methyltransferase (MGMT) promoter by high-resolution melting analysis, as this has been shown to be a predictive marker in GBM. MGMT methylation status correlated with progression-free survival (P = 0.0201; logrank test) as well as with overall survival (P = 0.0054; logrank test). MiR-195 (P = 0.0124; logrank test) and miR-196b (P = 0.0492; logrank test) positively correlated with overall survival. Evaluation of miR-181c in combination with miR-21 predicted time to progression within 6 months of diagnosis with 92% sensitivity and 81% specificity (P < 0.0001). Our data confirmed that the methylation status of MGMT but also miR-21, miR-181c, miR-195, and miR-196b to be associated with survival of GBM patients. Above all, we suggest that the combination of miR-181c and miR-21 could be a very sensitive and specific test to identify patients at high risk of early progression after surgery.
dcterms:title
MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients
skos:prefLabel
MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients
skos:notation
RIV/00209805:_____/11:#0000184!RIV12-MZ0-00209805
n11:predkladatel
n12:ico%3A00209805
n3:aktivita
n13:Z n13:I n13:S n13:P
n3:aktivity
I, P(ED0030/01/01), P(NS9875), P(NT11214), S, Z(MZ0MOU2005)
n3:cisloPeriodika
12
n3:dodaniDat
n10:2012
n3:domaciTvurceVysledku
n5:5818222 n5:6231616 n5:6760074 n5:5974291 n5:2912589 n5:5218578 n5:2632225
n3:druhVysledku
n17:J
n3:duvernostUdaju
n8:S
n3:entitaPredkladatele
n19:predkladatel
n3:idSjednocenehoVysledku
212672
n3:idVysledku
RIV/00209805:_____/11:#0000184
n3:jazykVysledku
n20:eng
n3:klicovaSlova
supresses tumorigenicity; anplastic astrocytoma; adjuvant temozolomide; microRNA-21; pathways; survival; radiotherapy
n3:klicoveSlovo
n6:anplastic%20astrocytoma n6:survival n6:adjuvant%20temozolomide n6:radiotherapy n6:pathways n6:supresses%20tumorigenicity n6:microRNA-21
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[A3FD4221C866]
n3:nazevZdroje
Cancer science
n3:obor
n9:FD
n3:pocetDomacichTvurcuVysledku
7
n3:pocetTvurcuVysledku
13
n3:projekt
n18:ED0030%2F01%2F01 n18:NT11214 n18:NS9875
n3:rokUplatneniVysledku
n10:2011
n3:svazekPeriodika
102
n3:tvurceVysledku
Svoboda, Marek Slabý, Ondřej Vyzula, Rostislav Lakomý, Radek Šána, Jiří Lžičařová, Eva Doleželová, Hana
n3:wos
000297202800010
n3:zamer
n14:MZ0MOU2005
s:issn
1347-9032
s:numberOfPages
5